Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis

• Published in: Rheumatology (Oxford, England) Vol. 57; no. 12; pp. 2114 - 2119
• Main Authors: Kurasawa, Kazuhiro, Arai, Satoko, Namiki, Yumeko, Tanaka, Ayae, Takamura, Yuta, Owada, Takayoshi, Arima, Masafumi, Maezawa, Reika
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.12.2018
• Subjects: Adult; Aged; Dermatomyositis - blood; Dermatomyositis - complications; Dermatomyositis - immunology; Drug Therapy, Combination; Female; Ferritins - blood; Glucocorticoids - administration & dosage; Humans; Interferon-Induced Helicase, IFIH1 - blood; Lung - pathology; Lung Diseases, Interstitial - drug therapy; Lung Diseases, Interstitial - immunology; Lung Diseases, Interstitial - pathology; Male; Middle Aged; Piperidines - therapeutic use; Prognosis; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - therapeutic use; Pyrroles - therapeutic use; Survival Rate; Treatment Outcome; immunosuppressive therapy; dermatomyositis; prognostic factors; interstitial lung disease; anti-MDA5 antibody; tofacitinib

Abstract Objective We aimed to determine the outcome of combination therapy with tofacitinib (TOF) in a case series of refractory rapidly progressive interstitial lung disease (ILD) associated with anti-melanoma differentiation-associated 5 gene (MDA5) antibody-positive (Ab+) DM. Patients who had po...